Mikel S Ehntholt1, Melvin Parasram1, Saad A Mir1,2, Mackenzie P Lerario3,4. 1. Department of Neurology, Weill Cornell Medicine, New York, NY, USA. 2. New York-Presbyterian Mobile Stroke Treatment Unit Program, New York, NY, USA. 3. Department of Neurology, Weill Cornell Medicine, New York, NY, USA. mpl9005@med.cornell.edu. 4. New York-Presbyterian Mobile Stroke Treatment Unit Program, New York, NY, USA. mpl9005@med.cornell.edu.
Abstract
PURPOSE OF REVIEW: Mobile stroke units (MSUs) have revolutionized emergency stroke care by delivering pre-hospital thrombolysis faster than conventional ambulance transport and in-hospital treatment. This review discusses the history of MSUs technological development, current operations and research, cost-effectiveness, and future directions. RECENT FINDINGS: Multiple prospective and retrospective studies have shown that MSUs deliver acute ischemic stroke treatment with intravenous recombinant tissue plasminogen activator (IV r-tPA) approximately 30 min faster than conventional care. The 90-day modified Rankin Scores for patients who received IV r-tPA on the MSU compared to conventional care were not statistically different in the PHANTOM-S study. Two German studies suggest that the MSU model is cost-effective by reducing disability and improving adjusted quality-life years post-stroke. The ongoing BEST-MSU trial will be the first multicenter, randomized controlled study that will shed light on MSUs' impact on long-term neurologic outcomes and cost-effectiveness. MSUs are effective in reducing treatment times in acute ischemic stroke without increasing adverse events. MSUs could potentially improve treatment times in large vessel occlusion and intracranial hemorrhage. Further studies are needed to assess functional outcomes and cost-effectiveness. Clinical trials are ongoing internationally.
RCT Entities:
PURPOSE OF REVIEW: Mobile stroke units (MSUs) have revolutionized emergency stroke care by delivering pre-hospital thrombolysis faster than conventional ambulance transport and in-hospital treatment. This review discusses the history of MSUs technological development, current operations and research, cost-effectiveness, and future directions. RECENT FINDINGS: Multiple prospective and retrospective studies have shown that MSUs deliver acute ischemic stroke treatment with intravenous recombinant tissue plasminogen activator (IV r-tPA) approximately 30 min faster than conventional care. The 90-day modified Rankin Scores for patients who received IV r-tPA on the MSU compared to conventional care were not statistically different in the PHANTOM-S study. Two German studies suggest that the MSU model is cost-effective by reducing disability and improving adjusted quality-life years post-stroke. The ongoing BEST-MSU trial will be the first multicenter, randomized controlled study that will shed light on MSUs' impact on long-term neurologic outcomes and cost-effectiveness. MSUs are effective in reducing treatment times in acute ischemic stroke without increasing adverse events. MSUs could potentially improve treatment times in large vessel occlusion and intracranial hemorrhage. Further studies are needed to assess functional outcomes and cost-effectiveness. Clinical trials are ongoing internationally.
Entities:
Keywords:
Acute stroke; Emergency medical services; Golden hour; Mobile stroke unit (MSU); Pre-hospital stroke treatment; Recombinant tissue plasminogen activator (r-tPA); Thrombolysis
Authors: Jose-Miguel Yamal; Suja S Rajan; Stephanie A Parker; Asha P Jacob; Michael O Gonzalez; Nicole R Gonzales; Ritvij Bowry; Andrew D Barreto; Tzu-Ching Wu; David R Lairson; David Persse; Barbara C Tilley; David Chiu; Jose I Suarez; William J Jones; Andrei Alexandrov; James C Grotta Journal: Int J Stroke Date: 2017-06-14 Impact factor: 5.266
Authors: Martin Ebinger; Benjamin Winter; Matthias Wendt; Joachim E Weber; Carolin Waldschmidt; Michal Rozanski; Alexander Kunz; Peter Koch; Philipp A Kellner; Daniel Gierhake; Kersten Villringer; Jochen B Fiebach; Ulrike Grittner; Andreas Hartmann; Bruno-Marcel Mackert; Matthias Endres; Heinrich J Audebert Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta Journal: Stroke Date: 2017-05-15 Impact factor: 7.914
Authors: Silke Walter; Iris Q Grunwald; Stefan A Helwig; Andreas Ragoschke-Schumm; Michael Kettner; Mathias Fousse; Martin Lesmeister; Klaus Fassbender Journal: Curr Atheroscler Rep Date: 2018-08-29 Impact factor: 5.113
Authors: Silke Walter; Henry Zhao; Damien Easton; Cees Bil; Jonas Sauer; Yang Liu; Martin Lesmeister; Iris Q Grunwald; Geoffrey A Donnan; Stephen M Davis; Klaus Fassbender Journal: Int J Stroke Date: 2018-08 Impact factor: 5.266
Authors: Seby John; Sarah Stock; Russell Cerejo; Ken Uchino; Stacey Winners; Andrew Russman; Thomas Masaryk; Peter Rasmussen; Muhammad S Hussain Journal: J Neuroimaging Date: 2015-11-23 Impact factor: 2.486
Authors: Jeffrey L Saver; Mayank Goyal; Aad van der Lugt; Bijoy K Menon; Charles B L M Majoie; Diederik W Dippel; Bruce C Campbell; Raul G Nogueira; Andrew M Demchuk; Alejandro Tomasello; Pere Cardona; Thomas G Devlin; Donald F Frei; Richard du Mesnil de Rochemont; Olvert A Berkhemer; Tudor G Jovin; Adnan H Siddiqui; Wim H van Zwam; Stephen M Davis; Carlos Castaño; Biggya L Sapkota; Puck S Fransen; Carlos Molina; Robert J van Oostenbrugge; Ángel Chamorro; Hester Lingsma; Frank L Silver; Geoffrey A Donnan; Ashfaq Shuaib; Scott Brown; Bruce Stouch; Peter J Mitchell; Antoni Davalos; Yvo B W E M Roos; Michael D Hill Journal: JAMA Date: 2016-09-27 Impact factor: 56.272
Authors: Ali Reza Noorian; Nerses Sanossian; Kristina Shkirkova; David S Liebeskind; Marc Eckstein; Samuel J Stratton; Franklin D Pratt; Robin Conwit; Fiona Chatfield; Latisha K Sharma; Lucas Restrepo; Miguel Valdes-Sueiras; May Kim-Tenser; Sidney Starkman; Jeffrey L Saver Journal: Stroke Date: 2018-02-19 Impact factor: 7.914
Authors: Sushanth Rao Aroor; Kaiz S Asif; Jennifer Potter-Vig; Arun Sharma; Bijoy K Menon; Violiza Inoa; Cynthia B Zevallos; Jose G Romano; Santiago Ortega-Gutierrez; Larry B Goldstein; Dileep R Yavagal Journal: J Stroke Date: 2022-01-31 Impact factor: 6.967